SCHEMBL5052173

SCHEMBL5052173

CNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cc(C(C)(C)C)nn4-c4ccc5ncncc5c4)c3)c(=O)n(C)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.47
SRC P12931 2/20 0.47
BRAF P15056 11/20 0.45
RAF1 P04049 5/20 0.45
MAPK14 Q16539 6/20 0.43
MAPK11 Q15759 3/20 0.43
MAPK12 P53778 3/20 0.43
MAPK13 O15264 2/20 0.43
KDR P35968 4/20 0.41
DDR2 Q16832 3/20 0.41
AXL P30530 2/20 0.41
PLK4 O00444 1/20 0.41
ACOX3 O15254 1/20 0.41
MAP3K7 O43318 1/20 0.41
DYRK3 O43781 1/20 0.41
JAK2 O60674 1/20 0.41
ERN1 O75460 1/20 0.41
RPS6KA4 O75676 1/20 0.41
STK10 O94804 1/20 0.41
MAP4K4 O95819 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5060539 0.91 ABL1 (0.55) ABL1SRCBRAFRAF1MAPK14
SCHEMBL5060109 0.89 MAPK14 (0.50) BRAFRAF1MAPK14MAPK11MAPK12
SCHEMBL4425259 0.88 MAPK14 (0.52) BRAFRAF1MAPK14MAPK11MAPK12
SCHEMBL5055112 0.87 MAPK14 (0.53) ABL1SRCBRAFRAF1MAPK14
SCHEMBL4427768 0.87 BRAF (0.49) BRAFRAF1MAPK14MAPK11MAPK12
SCHEMBL5055164 0.87 BRAF (0.45) ABL1SRCBRAFRAF1MAPK14
SCHEMBL5052306 0.87 BRAF (0.45) ABL1SRCBRAFRAF1MAPK14
SCHEMBL5059875 0.87 RAF1 (0.45) SRCBRAFRAF1MAPK14MAPK11
SCHEMBL5055144 0.87 BRAF (0.45) ABL1SRCBRAFRAF1MAPK14
SCHEMBL5056492 0.87 BRAF (0.47) BRAFRAF1MAPK14MAPK11MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 ABL1 20/4885SRC 69/4885BRAF 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.